| Pejman Cohan, M.d., Inc. | |
|
8816 Burton Way Beverly Hills CA 90211-1715 | |
| (310) 657-3030 | |
| (310) 657-9777 |
| Full Name | Pejman Cohan, M.d., Inc. |
|---|---|
| Speciality | Internal Medicine |
| Location | 8816 Burton Way, Beverly Hills, California |
| Authorized Official Name and Position | Pejman Cohan (PRESIDENT) |
| Authorized Official Contact | 3106573030 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Pejman Cohan, M.d., Inc. 8816 Burton Way Beverly Hills CA 90211-1715 Ph: (310) 657-3030 | Pejman Cohan, M.d., Inc. 8816 Burton Way Beverly Hills CA 90211-1715 Ph: (310) 657-3030 |
| NPI Number | 1538349865 |
|---|---|
| Provider Enumeration Date | 11/03/2007 |
| Last Update Date | 08/01/2020 |
| Medicare PECOS PAC ID | 4587683776 |
|---|---|
| Medicare Enrollment ID | O20051116000946 |
News Archive
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval Thursday of the first generic versions in the U.S. That's because the patent for Plavix, the world's second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.
The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538349865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | A61196 (California) | Primary |
| Provider Name | Pejman E Cohan |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1225064884 PECOS PAC ID: 8527050368 Enrollment ID: I20040331001734 |
News Archive
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval Thursday of the first generic versions in the U.S. That's because the patent for Plavix, the world's second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.
The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.
› Verified 8 days ago
News Archive
Black Medicare beneficiaries "fare worse" than white beneficiaries "even when they belong to the same health plan," an indication that health care disparities "cannot be attributed to individual, inferior doctors," according to a study published on Wednesday in the Journal of the American Medical Association, the Boston Globe reports.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval Thursday of the first generic versions in the U.S. That's because the patent for Plavix, the world's second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.
The Food and Drug Administration can promote progress toward personalized medicine by approaching the oversight of laboratory developed tests (LDTs) in a focused, flexible, and balanced way according to the American Clinical Laboratory Association (ACLA). ACLA, which represents the nation's leading clinical laboratories, says that the factors supporting this approach include the growing role that such tests play in clinical decision making, especially in the area of new advanced diagnostics that derive from the mapping of the human genome and help fulfill the promise of personalized medicine.
› Verified 8 days ago
Treatmedngo Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8950 W Olympic Blvd Ste 103&104, Beverly Hills, CA 90211 Phone: 310-274-8080 | |
Refael Medical, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8200 Wilshire Blvd, Beverly Hills, CA 90211 Phone: 310-879-7167 Fax: 310-933-5688 | |
Michael D. Borookhim, M.d., Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9301 Wilshire Blvd, Suite 602, Beverly Hills, CA 90210 Phone: 310-288-0881 | |
Ultrasound Specialists Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9001 Wilshire Blvd, Suite 106, Beverly Hills, CA 90211 Phone: 310-273-8885 | |
Kaiser Permanente Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 204 S Arnaz Dr Apt 3, Beverly Hills, CA 90211 Phone: 213-215-5142 | |
Nancy P. Rahnama, M.d., A.p.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 421 N Rodeo Dr, Penthouse Number 1, Beverly Hills, CA 90210 Phone: 310-299-7373 Fax: 310-432-6647 | |
Laurence Seigler, M.d. Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 435 N Bedford Dr, Suite 308, Beverly Hills, CA 90210 Phone: 310-274-6158 Fax: 310-274-5709 |